// App-Quantinova.ai

PB1921 : A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

Researchers

Presenter

  • Amy DeZern

Principal Investigators

  • Dries Deeren

  • Maria Diez Campelo

  • Michael Lbbert

  • Pramila Krishnamurthy

  • Zsolt Nagy

  • Grzegorz Basak

  • Anna Jonov

  • Elena Morozova

  • Klaus Geissler

  • Yishai Ofran

  • Heather Kelley

  • Angela Volkert

  • Qing Kang-Fortner

  • Graeme Hodgson

  • Catherine Madigan

  • David A. Roth

  • Michael Kelly

  • Pierre Fenaux

Medical Centers

  • General University Hospital Prague,Prague,Rep. Ceca

  • UniversitätKlinikum Freiburg,Freiburg,Duitsland

  • AGIOS Pharmaceuticals Inc,Cambridge,United States

  • Hospital Universitario de Salamanca,Salamanca,España

  • Hospital Universitario de Salamanca,Salamanca,España

  • Medical University of Warsaw, Warsaw, Poland

  • Semmelweis University, Department of Internal Medicine and Oncology, Hungary

  • Department of Hematology, Shaare Zedek Medical Center, Faculty of Medicine Hebrew University of Jerusalem,Jerusalem,Israël

  • Agios Pharmaceuticals Inc.,Cambridge,Estados Unidos

  • Hopital St. Louis,Paris,Francia

  • UniversitätKlinikum Freiburg,Freiburg,Duitsland

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Romagnolo Institute to Study Tumors 'Dino Amadori',Meldola,Италия

  • Medical University of Warsaw, Warsaw, Poland

  • Romagnolo Institute to Study Tumors 'Dino Amadori',Meldola,Италия

  • Medical University of Warsaw, Warsaw, Poland

  • Semmelweis University, Department of Internal Medicine and Oncology, Hungary

  • King's College Hospital,London,Reino Unido

  • Kings College Hospital,London,Verenigd Koninkrijk

  • Hopital Saint Louis,Paris,Франция

  • Universitaetsklinikum Freiburg,Freiburg,Германия

  • Hospital Hietzing,Vienna,Österreich

  • Agios Pharmaceuticals Inc.,Cambridge,Estados Unidos

  • Semmelweis University, Department of Internal Medicine and Oncology, Hungary

  • Department of Hematology, Shaare Zedek Medical Center, Faculty of Medicine Hebrew University of Jerusalem,Jerusalem,Israël

  • Hospital Hietzing, Vienna, Austria

  • Hospital Hietzing, Vienna, Austria

  • AGIOS Pharmaceuticals Inc,Cambridge,United States

  • Hospital Hietzing, Vienna, Austria

  • General Teaching Hospital in Prague, Prague, Czech Republic

  • Romagnolo Institute to Study Tumors 'Dino Amadori',Meldola,Италия

  • Johns Hopkins University,Baltimore, MD,États-unis

  • Agios Pharmaceuticals Inc.,Cambridge,Estados Unidos

  • AZ Delta, Roeselare, Belgium

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Universitatsklinikum Freiburg, Freiburg, Germany

  • Semmelweis University, First Department of Internal Medicine, Division of Haematology, Budapest, Hungary

  • Semmelweis University, Department of Internal Medicine and Oncology, Hungary

  • Department of Hematology, Shaare Zedek Medical Center, Faculty of Medicine Hebrew University of Jerusalem,Jerusalem,Israël

  • Haematology,King's College Hospital,London,Соединённое Королевство

  • General University Hospital Prague,Prague,Rep. Ceca

  • General University Hospital Prague,Prague,Rep. Ceca

  • Johns Hopkins University,Baltimore, MD,États-unis

  • AZ Delta, Roeselare, Belgium

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Johns Hopkins Hospital,Baltimore,Verenigde Staten

  • Hospital Universitario de Salamanca,Salamanca,España

  • Hospital Saint Antoine, Paris, France

  • Semmelweis University, Department of Internal Medicine and Oncology, Hungary

  • AZ Delta, Roeselare, Belgium

  • AZ Delta, Roeselare, Belgium

  • Romagnolo Institute to Study Tumors 'Dino Amadori',Meldola,Италия

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Agios Pharmaceuticals Inc.,Cambridge,Estados Unidos

  • UniversitätKlinikum Freiburg,Freiburg,Duitsland

  • Johns Hopkins Hospital,Baltimore,Verenigde Staten

  • UniversitätKlinikum Freiburg,Freiburg,Duitsland

  • Semmelweis University, Department of Internal Medicine and Oncology, Hungary

  • King's College Hospital,London,Reino Unido

  • Johns Hopkins University, Baltimore, MD

  • General University Hospital Prague,Prague,Tsjechische Republiek

  • Hospital Hietzing,Vienna,Österreich

  • Johns Hopkins University,Baltimore, MD,États-unis

  • General University Hospital Prague,Prague,Tsjechische Republiek

  • Romagnolo Institute to Study Tumors 'Dino Amadori',Meldola,Италия

  • Romagnolo Institute to Study Tumors 'Dino Amadori',Meldola,Италия

  • Department of Hematology, Shaare Zedek Medical Center, Faculty of Medicine Hebrew University of Jerusalem,Jerusalem,Israël

  • General University Hospital Prague,Prague,Rep. Ceca

  • Hospital Saint Antoine, Paris, France

  • Hopital St. Louis,Paris,Francia

  • Semmelweis University, Department of Internal Medicine and Oncology, Hungary

  • Romagnolo Institute to Study Tumors 'Dino Amadori',Meldola,Италия

  • Kings College Hospital,London,Vereinigtes Königreich

  • AZ Delta,Roeselare,Bélgica

  • Hospital Universitario de Salamanca,Salamanca,España

  • Haematology,King's College Hospital,London,Storbritannien

  • General University Hospital Prague,Prague,Rep. Ceca

  • Hospital Saint Antoine, Paris, France

  • Medical University of Warsaw, Warsaw, Poland

  • Medical University of Warsaw,Warsaw,Польша

  • UniversitätKlinikum Freiburg,Freiburg,Duitsland

  • King's College Hospital,London,Royaume-uni

  • General University Hospital Prague,Prague,Tsjechische Republiek

  • Hospital Hietzing,Vienna,Австрия

  • Semmelweis University, Department of Internal Medicine and Hematology,Budapest,Венгрия

  • UniversitätKlinikum Freiburg,Freiburg,Duitsland

  • Hospital Hietzing,Vienna,Österreich

  • John Hopkins University, Baltimore, Maryland, United States

  • AZ Delta, Roeselare, Belgium

  • Universitatsklinikum Freiburg, Freiburg, Germany

  • Hospital Saint Antoine, Paris, France

  • AGIOS Pharmaceuticals Inc,Cambridge,United States

  • Kings College London, London, United Kingdom

Locations

  • United States

  • Italy

  • Belgium

  • Mexico

  • Spain

  • Germany

  • United Kingdom

  • Hungary

  • Poland

  • Czech Republic

  • Russia

  • Austria

  • Israel

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • Hormone receptor

Drug/Treatment

  • Tamibarotene

  • Vidaza

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved